BLUE SAIL MEDICAL(002382)2025-01-24 09:40Financial Performance - The company expects a net loss of approximately 370 million yuan for the reporting period, an improvement from a loss of 568.36 million yuan in the same period last year, representing a year-on-year decrease of 34.90%[3]. - The emergency rescue division is expected to achieve a profit of approximately 30 million yuan during the reporting period, while continuing to develop markets in the Americas and domestically[6]. - The company anticipates a potential impairment of long-term equity investments between 10 million and 30 million yuan, subject to final assessment[7]. Revenue Growth - The cardiovascular division achieved sales revenue exceeding 1.1 billion yuan, a year-on-year increase of about 12%, with a gross margin improvement[5]. - The health protection division's revenue grew by over 33% year-on-year, nearing breakeven, with glove product sales volume increasing nearly 29% compared to the previous year[5]. - The Asia-Pacific region's sales revenue grew approximately 23%, driven by increased sales of coronary and valve products[5]. Strategic Investments and Liabilities - The company has secured a strategic investment of 1 billion yuan from external investors for its subsidiary, which will be recognized as a financial liability due to potential buyback obligations[6]. Research and Development - The cardiovascular division's R&D expenses remain around 200 million yuan, aimed at enhancing product competitiveness[5]. Cost Management - The company has implemented cost reduction and efficiency enhancement measures, resulting in a gross margin increase of about 8 percentage points in the health protection division[5]. Communication and Forecasting - The company has communicated with the accounting firm regarding the performance forecast, with no significant discrepancies noted[4].